On May 4th 2020 a GrandChallenge entitled "Billion molecules against Covid-19" was launched by the Joint European Disruptive Initiative (JEDI). Teams from all over the world provided lists of compounds with suspected inhibitory properties versus specific SARS-CoV-2 and human host protein targets. Here we disclose 878 compounds, which were selected by the 20 top-ranked teams ('finalists'). Some finalists teams did not have compounds produced, because they were either unstable or synthetically unfeasible. The compounds were synthesized thanks to JEDI fundraising, and are in the process of being tested in biophysical assays, cell-based assays, etc. Purity data for each compound by LC-MS (liquid chromatography mass spectrometry) is provided. The data file contains SMILES information, molecular weight, purity, and solubility information (in DMSO dimethylsulfoxide). The compounds should be active against either one of the following SARS-CoV-2 protein targets: nsp3, nsp5, nucleocapsid (N), Spike (S), or RdRp (Nsp12), or against human host target TMPRSS2. Authors are listed in random order. Some co-authors are members of the Scientific Committee or organizing team of the GrandChallenge. All work has been performed with an open science mindset, and all data will be shared in the public domain. A publication is in preparation to disclose the experimental results. In version 1 of this data set it is likely that some co-author data is missing, which will be corrected in following versions. The data has been made public by the program manager of the GrandChallenge, Prof. Thomas M. Hermans. Author contributions are also available in spreadsheet format. Please contact [email protected] for more information, or check https://www.jedi.foundation/


About JEDI - The Joint European Disruptive Initiative (JEDI) seeks to bring Europe in a leadership position in breakthrough technologies by launching Scientific and Technology GrandChallenges to push the frontiers of innovation. It is the European advanced research projects agency (ARPA) with a radical method based on excellence, speed, high expectations, bold risk-taking & no geographical return to solve major societal issues in environment, healthcare, digital, education, oceans & space. Driven by humanistic values, JEDI is a not-for-profit organization financed by foundations, governments, corporates and powered by the contribution of 4.100 technology and scientific leaders from academia, corporations and deeptech startups in 29 countries in Europe.
update 30/06/2021 17:32 CET: 12 additional co-authors added, and updated acknowledgement spreadsheet

On May 4th 2020 a GrandChallenge entitled "Billion molecules against Covid-19" was launched by the Joint European Disruptive Initiative (JEDI). Teams from all over the world provided lists of compounds with suspected inhibitory properties versus specific SARS-CoV-2 and human host protein targets. Here we disclose 878 compounds, which were selected by the 20 top-ranked teams ('finalists'). Some finalists teams did not have compounds produced, because they were either unstable or synthetically unfeasible. The compounds were synthesized thanks to JEDI fundraising, and are in the process of being tested in biophysical assays, cell-based assays, etc. Purity data for each compound by LC-MS (liquid chromatography mass spectrometry) is provided. The data file contains SMILES information, molecular weight, purity, and solubility information (in DMSO dimethylsulfoxide). The compounds should be active against either one of the following SARS-CoV-2 protein targets: nsp3, nsp5, nucleocapsid (N), Spike (S), or RdRp (Nsp12), or against human host target TMPRSS2. Authors are listed in random order. Some co-authors are members of the Scientific Committee or organizing team of the GrandChallenge. All work has been performed with an open science mindset, and all data will be shared in the public domain. A publication is in preparation to disclose the experimental results. In version 1 of this data set it is likely that some co-author data is missing, which will be corrected in following versions. The data has been made public by the program manager of the GrandChallenge, Prof. Thomas M. Hermans. Author contributions are also available in spreadsheet format. Please contact [email protected] for more information, or check https://www.jedi.foundation/


About JEDI - The Joint European Disruptive Initiative (JEDI) seeks to bring Europe in a leadership position in breakthrough technologies by launching Scientific and Technology GrandChallenges to push the frontiers of innovation. It is the European advanced research projects agency (ARPA) with a radical method based on excellence, speed, high expectations, bold risk-taking & no geographical return to solve major societal issues in environment, healthcare, digital, education, oceans & space. Driven by humanistic values, JEDI is a not-for-profit organization financed by foundations, governments, corporates and powered by the contribution of 4.100 technology and scientific leaders from academia, corporations and deeptech startups in 29 countries in Europe.

On May 4th 2020 a GrandChallenge entitled "Billion molecules against Covid-19" was launched by the Joint European Disruptive Initiative (JEDI). Teams from all over the world provided lists of compounds with suspected inhibitory properties versus specific SARS-CoV-2 and human host protein targets. Here we disclose 878 compounds, which were selected by the 20 top-ranked teams ('finalists'). Some finalists teams did not have compounds produced, because they were either unstable or synthetically unfeasible. The compounds were synthesized thanks to JEDI fundraising, and are in the process of being tested in biophysical assays, cell-based assays, etc. Purity data for each compound by LC-MS (liquid chromatography mass spectrometry) is provided. The data file contains SMILES information, molecular weight, purity, and solubility information (in DMSO dimethylsulfoxide). The compounds should be active against either one of the following SARS-CoV-2 protein targets: nsp3, nsp5, nucleocapsid (N), Spike (S), or RdRp (Nsp12), or against human host target TMPRSS2. Authors are listed in random order. Some co-authors are members of the Scientific Committee or organizing team of the GrandChallenge. All work has been performed with an open science mindset, and all data will be shared in the public domain. A publication is in preparation to disclose the experimental results. In version 1 of this data set it is likely that some co-author data is missing, which will be corrected in following versions. The data has been made public by the program manager of the GrandChallenge, Prof. Thomas M. Hermans. Author contributions are also available in spreadsheet format. Please contact [email protected] for more information, or check https://www.jedi.foundation/


About JEDI - The Joint European Disruptive Initiative (JEDI) seeks to bring Europe in a leadership position in breakthrough technologies by launching Scientific and Technology GrandChallenges to push the frontiers of innovation. It is the European advanced research projects agency (ARPA) with a radical method based on excellence, speed, high expectations, bold risk-taking & no geographical return to solve major societal issues in environment, healthcare, digital, education, oceans & space. Driven by humanistic values, JEDI is a not-for-profit organization financed by foundations, governments, corporates and powered by the contribution of 4.100 technology and scientific leaders from academia, corporations and deeptech startups in 29 countries in Europe.

On May 4th 2020 a GrandChallenge entitled "Billion molecules against Covid-19" was launched by the Joint European Disruptive Initiative (JEDI). Teams from all over the world provided lists of compounds with suspected inhibitory properties versus specific SARS-CoV-2 and human host protein targets. Here we disclose 878 compounds, which were selected by the 20 top-ranked teams ('finalists'). Some finalists teams did not have compounds produced, because they were either unstable or synthetically unfeasible. The compounds were synthesized thanks to JEDI fundraising, and are in the process of being tested in biophysical assays, cell-based assays, etc. Purity data for each compound by LC-MS (liquid chromatography mass spectrometry) is provided. The data file contains SMILES information, molecular weight, purity, and solubility information (in DMSO dimethylsulfoxide). The compounds should be active against either one of the following SARS-CoV-2 protein targets: nsp3, nsp5, nucleocapsid (N), Spike (S), or RdRp (Nsp12), or against human host target TMPRSS2. Authors are listed in random order. Some co-authors are members of the Scientific Committee or organizing team of the GrandChallenge. All work has been performed with an open science mindset, and all data will be shared in the public domain. A publication is in preparation to disclose the experimental results. In version 1 of this data set it is likely that some co-author data is missing, which will be corrected in following versions. The data has been made public by the program manager of the GrandChallenge, Prof. Thomas M. Hermans. Author contributions are also available in spreadsheet format. Please contact [email protected] for more information, or check https://www.jedi.foundation/


About JEDI - The Joint European Disruptive Initiative (JEDI) seeks to bring Europe in a leadership position in breakthrough technologies by launching Scientific and Technology GrandChallenges to push the frontiers of innovation. It is the European advanced research projects agency (ARPA) with a radical method based on excellence, speed, high expectations, bold risk-taking & no geographical return to solve major societal issues in environment, healthcare, digital, education, oceans & space. Driven by humanistic values, JEDI is a not-for-profit organization financed by foundations, governments, corporates and powered by the contribution of 4.100 technology and scientific leaders from academia, corporations and deeptech startups in 29 countries in Europe.
update 30/06/2021 17:32 CET: 12 additional co-authors added, and updated acknowledgement spreadsheet